Votre parcours clé en main

Polyarthrite rhumatoïde – Pr Philippe Dieudé (Paris)

Spondyloarthrite – Pr Pascal Claudepierre (Créteil)

Maladies auto-immunes – Pr Christophe Richez (Bordeaux)

Le parcours d’or (3-4-5-6 juin)
Comorbidités et complications

• **OP0012** TNF inhibitors are associated with a reduced risk of venous thromboembolism compared to csDMARDs in RA patients – Martin Schaefer et al.  
  • Mercredi 3 juin  
  • 15 h 20-15 h 30 – Isomäki – Opening Plenary abstract session

• **OP0036** Methotrexate and rheumatoid arthritis associated interstitial lung disease – Pierre-Antoine Juge et al.  
  • Mercredi 3 juin  
  • 16 h 10-16 h 15 – Ansell – Abstract session “Lung diseases and other comorbidities in RA”

• **OP0037** Non-anti-TNF biologic agents are associated with less marked progression of interstitial lung disease secondary to rheumatoid arthritis – Natalia Mena-Vázquez et al.  
  • Mercredi 3 juin  
  • 16 h 15-16 h 20 – Ansell – Abstract session “Lung diseases and other comorbidities in RA”

• **OP0115** Effect of nintedanib on progression of interstitial lung disease (ILD) in patients with autoimmune disease-related ILDs: further data from the INBUILD trial – Eric Matteson et al.  
  • Jeudi 4 juin  
  • 10 h 55-11 h 05 – Kalden – Abstract session “Rheumatoid arthritis - prognosis, predictors and outcome I”

• **OP0232** Treatment with methotrexate and risk of lung disease in patients with rheumatoid arthritis: a nationwide population-based cohort study from Denmark – René Cordtz et al.  
  • Vendredi 5 juin  
  • 10 h 20-10 h 25 – Wollheim – Abstract session “Rheumatoid arthritis - Non biologic treatment and small molecules”

• **OP0124** Risk of malignancies across biologic classes in rheumatoid arthritis: analysis of a national claim database – Raphaèle Seror et al.  
  • Jeudi 4 juin  
  • 11 h 05-11 h 15 – Ansell – Abstract session “Cardiovascular disease and malignancies in RA”

• **OP0125** Lymphomas complicating rheumatoid arthritis: results of a French multi-centre case-control study – Joanna Kedra et al.  
  • Jeudi 4 juin  
  • 11 h 15-11 h 25 – Ansell – Abstract session “Cardiovascular disease and malignancies in RA”

• **OP0221** Have 5-year survival rate and mortality changed in patients with early rheumatoid arthritis in the past twenty years? Results from the IORRA cohort – Naohiro Sugitani et al.  
  • Vendredi 5 juin  
  • 11 h 05-11 h 15 – Kalden – Abstract session “Rheumatoid arthritis - Prognosis, predictors and outcome II”

• **OP0237** Thromboembolic safety profile of tofacitinib and baricitinib: an analysis of WHO VigiBase – Enriqueta Vallejo-Yagüe et al.  
  • Vendredi 5 juin  
  • 10 h 45-10 h 50 – Wollheim – Abstract session “Rheumatoid arthritis - Non biologic treatment and small molecules”

• **SAT0066** Burden of malignancy, venous thromboembolism, anemia, and infections in patients with rheumatoid arthritis who switched from a first conventional synthetic disease-modifying antirheumatic drug to another disease-modifying antirheumatic drug regimen – Jenya Antonova et al.  
  • Samedi 6 juin  
  • 10 h 30-12 h 10 – Poster tour “Infections and clinical aspects in RA”

• **SAT0134** Comparative risk of cancer associated with first-line DMARDs use in rheumatoid arthritis: real world evidence from the OHDSI network – Talita Duarte-Salles et al.  
  • Samedi 6 juin  
  • 10 h 30-12 h 10 – Poster tour “Rheumatoid arthritis - Non biologic treatment and small molecules”
Les clés de l’EULAR

Votre parcours clé en main

Polyarthrite rhumatoïde
— La sélection du Pr Philippe Dieudé (Paris)

Stratégies thérapeutiques

- **OP0019** Stable versus tapered and withdrawn treatment with tumor necrosis factor inhibitor in rheumatoid arthritis remission (ARCTIC REWIND): a randomised, open-label, phase 4, non-inferiority trial – Siri Lillegraven et al.
  - Mercredi 3 juin
  - 16 h 05-16 h 10 – Wollheim – Abstract session "Biological DMARDs in RA I"

- **OP0116** Ten-year analysis of very low-dose glucocorticoids in early RA (ESPOIR cohort) supports a time-dependent risk of severe outcomes – Bernard Combe et al.
  - Jeudi 4 juin
  - 11 h 05-11 h 15 – Kalden – Abstract session "Rheumatoid arthritis - prognosis, predictors and outcome I"

- **SAT0130** Treat-to-target strategy of >8,000 patients with early rheumatoid arthritis: Does smoking affect achievement of remission on methotrexate and time to start of first biologic? Results from the nationwide Danish DANBIO registry – Bente Glintborg et al.
  - Samedi 6 juin
  - 10 h 30-12 h 10 – Poster tour “Rheumatoid arthritis - Non biologic treatment and small molecules”

- **OP0116** Ten-year analysis of very low-dose glucocorticoids in early RA (ESPOIR cohort) supports a time-dependent risk of severe outcomes – Bernard Combe et al.
  - Jeudi 4 juin
  - 11 h 05-11 h 15 – Kalden – Abstract session "Rheumatoid arthritis - prognosis, predictors and outcome I"

Facteurs pronostiques

- **OP0023** Prediction of remission for each biologics based on patient’s clinical information before starting biologics using explainable artificial intelligence: data from the Korean College of Rheumatology Biologics Registry – Bon San Koo et al.
  - Mercredi 3 juin
  - 16 h 25-16 h 30 – Wollheim – Abstract session "Biological DMARD in RA I"

- **OP0216** Development and validation of patient-level prediction models for adverse health outcomes amongst adult RA patients initiating first-line treatment of methotrexate monotherapy: a multinational real-world cohort analysis including 164,735 subjects – Cynthia Yang et al.
  - Vendredi 5 juin
  - 10 h 15-10 h 25 – Kalden – Abstract session "Rheumatoid arthritis - Prognosis, predictors and outcome II"

- **OP0222** Is referring early arthritis patients within 6 weeks associated with better long-term outcomes than referring within 12 weeks after symptom onset? – Investigating the evidence for the first EULAR recommendation for early arthritis in two observational cohorts – Ellis Niemantsverdriet et al.
  - Vendredi 5 juin
  - 11 h 15-11 h 25 – Kalden – Abstract session "Rheumatoid arthritis - Prognosis, predictors and outcome II"

- **OP0235** Achieving a low DAS in the first 4-months after diagnosis is important for the long-term chance of achieving DMARD-free remission – Marloes Verstappen et al.
  - Vendredi 5 juin
  - 10 h 35-10 h 40 – Wollheim – Abstract session "Rheumatoid arthritis - Non biologic treatment and small molecules"

- **SAT0137** Methotrexate associated adverse events and their predictors in methotrexate-naïve patients with rheumatoid arthritis: a systematic review – Ahmad Sherbini et al.
  - Samedi 6 juin
  - 1 h 00-1 h 05 – Poster tour “Rheumatoid arthritis - Non biologic treatment and small molecules”
Polyarthrite rhumatoïde
— La sélection du Pr Philippe Dieudé (Paris)

Pré-PR
- OP0114 Predicting rheumatoid arthritis using the Symptoms in Persons At Risk of Rheumatoid Arthritis (SPARRA) questionnaire – Laurette van Boheemen et al.
  • Jeudi 4 juin
  • 10 h 45-10 h 55 – Kalden – Abstract session “Rheumatoid arthritis - Prognosis, predictors and outcome I”
- SAT0071 Subclinical synovitis in arthralgia: how often does it result in clinical arthritis? A longitudinal study to reflect on starting points for DMARD treatment – Cleo Rogier et al.
  • Samedi 6 juin
  • 10 h 30-12 h 10 – Poster tour “Infections and clinical aspects in RA”
Spondyloarthrite

— La sélection du Pr Pascal Claudepierre (Créteil)

Rhumatisme psoriasique

Actualités thérapeutiques : traitements actuels et futurs

- **OP0050 Adalimumab introduction versus methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis: results from randomized phase 4 CONTROL study** – Laura C. Coates et al.
  - Mercredi 3 juin
  - 16 h 00-16 h 05 – Tan – Abstract session "Psoriatic arthritis and its management: More than just synovitis"

- **OP0054 Efficacy of guselkumab, a monoclonal antibody that specifically binds to the p19-subunit of IL-23, on endpoints related to axial involvement in patients with active PsA with imaging-confirmed sacroiliitis: week-24 results from two phase 3, randomized, double-blind, placebo-controlled studies** – Philip Helliwell et al.
  - Mercredi 3 juin
  - 16 h 20-16 h 25 – Tan – Abstract session "Psoriatic arthritis and its management: More than just synovitis"

- **OP0056 Persistence of biologic treatment in psoriatic arthritis: a population-based study in Sweden** – Kirk Geale et al.
  - Mercredi 3 juin
  - 16 h 30-16 h 35 – Tan – Abstract session "Psoriatic arthritis and its management: More than just synovitis"

- **SAT0398 Persistence of ustekinumab (UST) or TNF inhibitor (TNFI) treatment in psoriatic arthritis (PsA): insights from the large, prospective, multinational, real-world PsABio cohort** – Laure Gossec et al.
  - Samedi 6 juin
  - 10 h 30-10 h 40 – Poster tour "Psoriatic arthritis: A heterogeneous poster tour thru a heterogeneous disease"

- **OP0223 Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and inadequate response to biologic disease-modifying anti-rheumatic drugs (SELECT-PsA-2): a double-blind, randomized controlled phase 3 trial** – Philip J. Mease et al.
  - Vendredi 5 juin
  - 10 h 15-10 h 25 – Ansell – Abstract session "Update on new treatment options for psoriatic arthritis"

• **2019 Update of the recommendations for the management of psoriatic arthritis with pharmacological therapies** – Laure Gossec
  - Samedi 6 juin
  - 13 h 40-13 h 50 – Valkenburg – Highlight session "EULAR Recommendations 2020"

Mise à jour des recommandations EULAR

- **OP0224 Filgotinib treatment leads to rapid and sustained reductions in inflammatory biomarkers in patients with moderate to severe psoriatic arthritis** – Dafna D. Gladman et al.
  - Vendredi 5 juin
  - 10 h 25-10 h 35 – Ansell – Abstract session "Update on new treatment options for psoriatic arthritis"

- **OP0225 Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib + methotrexate: a randomised, placebo-controlled substudy of OPAL balance** – Peter Nash et al.
  - Vendredi 5 juin
  - 10 h 35-10 h 45 – Ansell – Abstract session "Update on new treatment options for psoriatic arthritis"

- **OP0227 Secukinumab versus adalimumab head-to-head comparison in biologic-naïve patients with active psoriatic arthritis through 52-weeks (EXCEED): a randomised, double-blind, phase-3b study** – Iain McInnes et al.
  - Vendredi 5 juin
  - 10 h 55-11 h 05 – Ansell – Abstract session "Update on new treatment options for psoriatic arthritis"

- **OP0228 Efficacy and safety of ixekizumab versus adalimumab (SPIRIT-H2H) with and without concomitant conventional synthetic Disease-Modifying Antirheumatic Drugs (DMARD) in biologic DMARD-naïve patients with psoriatic arthritis: 52-week results** – Josef S. Smolen et al.
  - Vendredi 5 juin
  - 11 h 05-11 h 15 – Ansell – Abstract session "Update on new treatment options for psoriatic arthritis"
Spondyloarthrite
—— La sélection du Pr Pascal Claudepierre (Créteil)

Spondyloarthrite axiale

**Traitement**

- **OP0106 Secukinumab 150 mg significantly improved signs and symptoms of non-radiographic axial spondyloarthritis: 52-week results from the phase III PREVENT study** – Juergen Braun et al.
  - Jeudi 4 juin
  - 10 h 45-10 h 55 – Amor – Abstract session “Spondyloarthritis treatment”

- **OP0107 Etanercept withdrawal and re-treatment in patients with inactive non-radiographic axial spondyloarthritis at 24 weeks: results of RE-EMBARK, an open-label, phase IV trial** – Filip van den Bosch et al.
  - Jeudi 4 juin
  - 10 h 55-11 h 05 – Amor – Abstract session “Spondyloarthritis treatment”

- **OP0109 Co-medication with a conventional synthetic DMARD in patients with axial spondylarthritis is associated with improved retention of TNF inhibitors: results from the EuroSpA collaboration** – Michael Nissen et al.
  - Jeudi 4 juin
  - 11 h 15-11 h 25 – Amor – Abstract session “Spondyloarthritis treatment”

- **OP0110 Is very early treatment effective? Six months results of the PREVAS study, a placebo-controlled trial with etanercept in patients suspected of non-radiographic axial spondyloarthritis** – Tamara Rusman et al.
  - Jeudi 4 juin
  - 11 h 25-11 h 35 – Amor – Abstract session “Spondyloarthritis treatment”

**Risque d’uvéites et biologiques**

- **OP0014 Comparison of anterior uveitis occurrence during treatment with secukinumab, adalimumab, infliximab and etanercept in spondyloarthritis** – Ulf Lindström et al.
  - Mercredi 3 juin
  - 15 h 40-15 h 50 – Isomäki – Opening Plenary Abstract session

Spondyloarthrite axiale et rhumatisme psoriasique

**Risque cardiovasculaire**

- **OP0002 Incidence of first cardiovascular event in Spanish patients with chronic inflammatory rheumatic diseases: prospective data from the CARMA project after 5 years of follow-up** – Santos Castañeda et al.
  - Mercredi 3 juin
  - 15 h 00-15 h 05 – Wollheim – Clinical science session “Cardiovascular risk and management in IMIDS”
Maladies auto-immunes  
— La sélection du Pr Christophe Richez (Bordeaux)

COVID-19

• Recommandations et 4 présentations de travaux originaux de dernière minute sur le sujet  
  • Mercredi 3 juin  
  • 16 h 30-17 h 30 – Bywaters – COVID session “EULAR COVID-19 Recommendations”

Lupus systémique

Physiopathologie

• OP0091 A two-score interferon signature and musculoskeletal imaging explain the association between interferon and arthritis in SLE – Zoe Wigston et al.  
  • Mercredi 3 juin  
  • 16 h 00-16 h 05 – Aho – Abstract session “SLE, Sjogren and APS clinical aspects”

Clinique

• OP0179 USEFUL study I: a multicentre longitudinal study to test whether ultrasound can identify patients with musculoskeletal symptoms of lupus with better response to therapy – Edward Vital et al.  
  • Jeudi 4 juin  
  • 10 h 45-10 h 55 – Tan – Abstract session “Diagnostics and imaging procedures”

Traitement

• OP0003 Early and sustained responses with anifrolumab treatment in patients with active systemic lupus erythematosus (SLE) in 2 phase 3 trials – Eric F. Morand et al.  
  • Mercredi 3 juin  
  • 14 h 45-14 h 50 – Amor – From bench to bedside

  • Mercredi 3 juin  
  • 16 h 35-16 h 40 – Dequeker – Abstract session “Pathogenic insights transforming the treatment of Sjögren’s and SLE 2020 and beyond”

• OP0193 BIIB059, a humanized monoclonal antibody targeting BDCA2 on plasmacytoid Dendritic Cells (pDC), shows dose-related efficacy in the phase 2 LILAC study in patients (pts) with active Cutaneous Lupus Erythematosus (CLE) – Victoria Werth et al.  
  • Jeudi 4 juin  
  • 16 h 45-16 h 50 – Bywaters – From bench to bedside

• OP0163 2019 update of the Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis – Antonis Fanouriakis et al.  
  • Jeudi 4 juin  
  • 10 h 45-10 h 55 – Aho – Abstract session “Advances in treating SLE and lupus nephritis”

  • Jeudi 4 juin  
  • 10 h 55-11 h 05 – Aho – Abstract session “Advances in treating SLE and lupus nephritis”

• OP0165 Long-term outcome of a randomized controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy of severe lupus nephritis – Chi Chiu Mok et al.  
  • Jeudi 4 juin  
  • 11 h 05-11 h 15 – Aho – Abstract session “Advances in treating SLE and lupus nephritis”
**Maladies auto-immunes**

— La sélection du Pr Christophe Richez (Bordeaux)

- **OP0167** Successful withdrawal of mycophenolate mofetil in quiescent SLE: results from a randomized trial – Eliza Chakravarty et al.
  - Jeudi 4 juin
  - 11 h 25-11 h 35 – Aho – Abstract session “Advances in treating SLE and lupus nephritis”

- **OP0277** AURORA phase 3 study demonstrates voclosporin statistical superiority over standard of care in lupus nephritis – Cristina Arriens et al.
  - Vendredi 5 juin
  - 11 h 25-11 h 35 – Aho – Abstract session “Other orphan diseases”

---

**Syndrome de Gougerot-Sjögren**

**Traitement**

- **OP0302** Ianalumab (VAY736), a dual mode of action biologic combining BAFF receptor inhibition with B cell depletion, reaches primary endpoint for treatment of primary Sjögren’s syndrome – Thomas Dörner et al.
  - Vendredi 5 juin
  - 13 h 00-13 h 05 – Ansell – Clinical science session “The new art of phenotyping and treating Sjögren’s syndrome”

---

**Sclérodermie systémique**

**Physiopathologie**

- **OP0013** Single cell profile of skin stromal and immune cells and peripheral blood immune cells of scleroderma patients towards identification of disease mechanism, prognostic biomarkers and potential therapeutic targets – Chamutal Gur et al.
  - Mercredi 3 juin
  - 15 h 30-15 h 40 – Isomäki – “Opening Plenary Abstract session”

**Traitement**

- **OP0249** Long-term extension results of RISE-SSc, a randomized trial of riociguat in patients with early diffuse cutaneous systemic sclerosis (dcSSc) – Dinesh Khanna et al.
  - Vendredi 5 juin
  - 10 h 35-10 h 45 – Nuki – Abstract session “Progress in scleroderma and myositis”

- **OP0250** Efficacy and safety of romilkimab in diffuse cutaneous systemic sclerosis (dcSSc): randomized, double-blind, placebo-controlled, 24-week, proof of concept study – Yannick Allanore et al.
  - Vendredi 5 juin
  - 10 h 45-10 h 55 – Nuki – Abstract session “Progress in scleroderma and myositis”
Maladies auto-immunes
— La sélection du Pr Christophe Richez (Bordeaux)

Vascularite

Outil diagnostique

- OP0150 What is the role of temporal artery biopsy in giant cell arteritis fast-track pathways when temporal artery ultrasound is negative? – Shirish Dubey et al.
  - Jeudi 4 juin
  - 11 h 25-11 h 35 – Rau – Abstract session “Vasculitis”

Traitement

- OP0011 A randomized, double-blind, active-controlled study of avacopan in Anti-Neutrophil Cytoplasmic Antibody (ANCA)-associated vasculitis – Peter A Merkel et al.
  - Mercredi 3 juin
  - 15 h 10-15 h 20 – Isomäki – “Opening Plenary Abstract session”

  - Mercredi 3 juin
  - 16 h 00-16 h 05 – Rau – Abstract session “Vasculitis”

- OP0029 Maintenance treatment for ANCA-associated vasculitis in real world practice in Europe – Reality of vasculitis remission and relapse and significant burden of disease – Peter Rutherford et al.
  - Mercredi 3 juin
  - 16 h 15-16 h 20 – Rau – Abstract session “Vasculitis”

  - Mercredi 3 juin
  - 16 h 20-16 h 25 – Rau – Abstract session “Vasculitis”
<table>
<thead>
<tr>
<th>Thématique auto-immunes</th>
<th>Horaires</th>
<th>Abstracts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maladies auto-immunes</td>
<td>14 h 45-14 h 50</td>
<td>OP0003 Early and sustained responses with anifrolumab treatment in patients with active systemic lupus erythematosus (SLE) in 2 phase 3 trials</td>
</tr>
<tr>
<td>Spondyloarthrite</td>
<td>15 h 00-15 h 05</td>
<td>OP0002 Incidence of first cardiovascular event in Spanish patients with chronic inflammatory rheumatic diseases: prospective data from the CARMA project after 5 years of follow-up</td>
</tr>
<tr>
<td>Maladies auto-immunes</td>
<td>15 h 10-15 h 20</td>
<td>OP0011 A randomized, double-blind, active-controlled study of avacopan in Anti-Neutrophil Cytoplasmic Antibody (ANCA)-associated vasculitis</td>
</tr>
<tr>
<td>Polyarthrite rhumatoïde</td>
<td>15 h 20-15 h 30</td>
<td>OP0012 TNF inhibitors are associated with a reduced risk of venous thromboembolism compared to csDMARDs in RA patients</td>
</tr>
<tr>
<td>Maladies auto-immunes</td>
<td>15 h 30-15 h 40</td>
<td>OP0013 Single cell profile of skin stromal and immune cells and peripheral blood immune cells of scleroderma patients towards identification of disease mechanism, prognostic biomarkers and potential therapeutic targets</td>
</tr>
<tr>
<td>Spondyloarthrite</td>
<td>15 h 40-15 h 50</td>
<td>OP0014 Comparison of anterior uveitis occurrence during treatment with secukinumab, adalimumab, infliximab and etanercept in spondyloarthritis</td>
</tr>
<tr>
<td>Polyarthrite rhumatoïde</td>
<td>16 h 00-16 h 05</td>
<td>OP0050 Adalimumab introduction versus methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis: results from randomized phase 4 CONTROL study</td>
</tr>
<tr>
<td>Maladies auto-immunes</td>
<td>16 h 00-16 h 05</td>
<td>OP0091 A two-score interferon signature and musculoskeletal imaging explaining the association between interferon and arthritis in SLE</td>
</tr>
<tr>
<td>Maladies auto-immunes</td>
<td>16 h 00-16 h 05</td>
<td>OP0026 A randomized, controlled trial of rituximab versus azathioprine after induction of remission with rituximab for patients with ANCA-associated vasculitis and relapsing disease</td>
</tr>
<tr>
<td>Polyarthrite rhumatoïde</td>
<td>16 h 05-16 h 10</td>
<td>OP0019 Stable versus tapered and withdrawn treatment with tumor necrosis factor inhibitor in rheumatoid arthritis remission (ARCTIC REWIND): a randomised, open-label, phase 4, non-inferiority trial</td>
</tr>
<tr>
<td>Polyarthrite rhumatoïde</td>
<td>16 h 10-16 h 15</td>
<td>OP0036 Methotrexate and rheumatoid arthritis associated interstitial lung disease</td>
</tr>
<tr>
<td>Polyarthrite rhumatoïde</td>
<td>16 h 15-16 h 20</td>
<td>OP0037 Non-anti-TNF biologic agents are associated with less marked progression of interstitial lung disease secondary to rheumatoid arthritis</td>
</tr>
<tr>
<td>Maladies auto-immunes</td>
<td>16 h 15-16 h 20</td>
<td>OP0029 Maintenance treatment for ANCA-associated vasculitis in real world practice in Europe – Reality of vasculitis remission and relapse and significant burden of disease</td>
</tr>
<tr>
<td>Maladies auto-immunes</td>
<td>16 h 20-16 h 25</td>
<td>OP0030 Granulomatosis with polyangitis sustained remission off-therapy: data from the French Vasculitis Study Group Registry</td>
</tr>
<tr>
<td>Spondyloarthrite</td>
<td>16 h 20-16 h 25</td>
<td>OP0054 Efficacy of guselkumab, a monoclonal antibody that specifically binds to the p19-subunit of IL-23, on endpoints related to axial involvement in patients with active PsA with imaging-confirmed sacroiliitis: week-24 results from two phase 3, randomized, double-blind, placebo-controlled studies</td>
</tr>
<tr>
<td>Polyarthrite rhumatoïde</td>
<td>16 h 25-16 h 30</td>
<td>OP0023 Prediction of remission for each biologics based on patient’s clinical information before starting biologics using explainable artificial intelligence: data from the Korean College of Rheumatology Biologics Registry</td>
</tr>
<tr>
<td>Spondyloarthrite</td>
<td>16 h 30-16 h 35</td>
<td>OP0056 Persistence of biologic treatment in psoriatic arthritis: a population-based study in Sweden</td>
</tr>
<tr>
<td>Maladies auto-immunes</td>
<td>16 h 30-17 h 30</td>
<td>COVID session “EULAR COVID-19 Recommendations”</td>
</tr>
<tr>
<td>Maladies auto-immunes</td>
<td>16 h 35-16 h 40</td>
<td>OP0049 Efficacy of anifrolumab in active systemic lupus erythematosus: patient subgroup analysis of BICLA response in 2 phase 3 trials</td>
</tr>
<tr>
<td>Thématique</td>
<td>Horaires</td>
<td>Abstracts</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>--------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Polyarthrite rhumatoïde</td>
<td>10h45-10h55</td>
<td>OP0114 Predicting rheumatoid arthritis using the Symptoms in Persons At Risk of Rheumatoid Arthritis (SPARRA) questionnaire</td>
</tr>
<tr>
<td>Spondyloarthrite</td>
<td>10h45-10h55</td>
<td>OP0106 Secukinumab 150 mg significantly improved signs and symptoms of non-radiographic axial spondyloarthritis: 52-week results from the phase III PREVENT study</td>
</tr>
<tr>
<td>Maladies auto-immunes</td>
<td>10h45-10h55</td>
<td>OP0179 USEFUL study I: a multicentre longitudinal study to test whether ultrasound can identify patients with musculoskeletal symptoms of lupus with better response to therapy</td>
</tr>
<tr>
<td>Maladies auto-immunes</td>
<td>10h45-10h55</td>
<td>OP0163 2019 update of the Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis</td>
</tr>
<tr>
<td>Maladies auto-immunes</td>
<td>10h55-11h05</td>
<td>OP0164 BLISS-LN: a randomised, double-blind, placebo-controlled phase 3 trial of intravenous belimumab in patients with active lupus nephritis</td>
</tr>
<tr>
<td>Spondyloarthrite</td>
<td>10h55-11h05</td>
<td>OP0107 Etanercept withdrawal and re-treatment in patients with inactive non-radiographic axial spondyloarthritis at 24 weeks: results of RE-EMBARK, an open-label, phase IV trial</td>
</tr>
<tr>
<td>Polyarthrite rhumatoïde</td>
<td>10h55-11h05</td>
<td>OP0115 Effect of nintedanib on progression of interstitial lung disease (ILD) in patients with autoimmune disease-related ILDs: further data from the INBUILD trial</td>
</tr>
<tr>
<td>Polyarthrite rhumatoïde</td>
<td>11h05-11h15</td>
<td>OP0124 Risk of malignancies across biologic classes in rheumatoid arthritis: analysis of a national claim database</td>
</tr>
<tr>
<td>Maladies auto-immunes</td>
<td>11h05-11h15</td>
<td>OP0165 Long-term outcome of a randomized controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy of severe lupus nephritis</td>
</tr>
<tr>
<td>Polyarthrite rhumatoïde</td>
<td>11h05-11h15</td>
<td>OP0116 Ten-year analysis of very low-dose glucocorticoids in early RA (ESPOIR cohort) supports a time-dependent risk of severe outcomes</td>
</tr>
<tr>
<td>Polyarthrite rhumatoïde</td>
<td>11h15-11h25</td>
<td>OP0125 Lymphomas complicating rheumatoid arthritis: results of a French multi-centre case-control study</td>
</tr>
<tr>
<td>Spondyloarthrite</td>
<td>11h15-11h25</td>
<td>OP0109 Co-medication with a conventional synthetic DMARD in patients with axial spondylarthritis is associated with improved retention of TNF inhibitors: results from the EuroSpA collaboration</td>
</tr>
<tr>
<td>Spondyloarthrite</td>
<td>11h25-11h35</td>
<td>OP0110 Is very early treatment effective? Six months results of the PREVAS study, a placebo-controlled trial with etanercept in patients suspected of non-radiographic axial spondyloarthritis</td>
</tr>
<tr>
<td>Maladies auto-immunes</td>
<td>11h25-11h35</td>
<td>OP0167 Successful withdrawal of mycophenolate mofetil in quiescent SLE: results from a randomized trial</td>
</tr>
<tr>
<td>Maladies auto-immunes</td>
<td>11h25-11h35</td>
<td>OP0150 What is the role of temporal artery biopsy in giant cell arteritis fast-track pathways when temporal artery ultrasound is negative?</td>
</tr>
<tr>
<td>Maladies auto-immunes</td>
<td>16h45-16h50</td>
<td>OP0193 BLI8059, a humanized monoclonal antibody targeting BDCA2 on plasmacytoid Dendritic Cells (pDC), shows dose-related efficacy in the phase 2 LILAC study in patients (pts) with active Cutaneous Lupus Erythematosus (CLE)</td>
</tr>
</tbody>
</table>
## VENDREDI 5 JUIN

<table>
<thead>
<tr>
<th>Thématique</th>
<th>Horaires</th>
<th>Abstracts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Polyarthrite rhumatoïde</td>
<td>10h15-10h25</td>
<td>OP0216 Development and validation of patient-level prediction models for adverse health outcomes amongst adult RA patients initiating first-line treatment of methotrexate monotherapy: a multinational real-world cohort analysis including 164,735 subjects</td>
</tr>
<tr>
<td>Spondyloarthrite</td>
<td>10h15-10h25</td>
<td>OP0223 Efficacy and Safety of upadacitinib in patients with active psoriatic arthritis and inadequate response to biologic disease-modifying anti-rheumatic drugs (SELECT-PsA-2): a double-blind, randomized controlled phase 3 trial</td>
</tr>
<tr>
<td>Polyarthrite rhumatoïde</td>
<td>10h20-10h25</td>
<td>OP0232 Treatment with methotrexate and risk of lung disease in patients with rheumatoid arthritis: a nationwide population-based cohort study from Denmark</td>
</tr>
<tr>
<td>Spondyloarthrite</td>
<td>10h25-10h35</td>
<td>OP0224 Filgotinib treatment leads to rapid and sustained reductions in inflammatory biomarkers in patients with moderate to severe psoriatic arthritis</td>
</tr>
<tr>
<td>Polyarthrite rhumatoïde</td>
<td>10h35-10h40</td>
<td>OP0235 Achieving a low DAS in the first 4-months after diagnosis is important for the long-term chance of achieving DMARD-free remission</td>
</tr>
<tr>
<td>Spondyloarthrite</td>
<td>10h35-10h45</td>
<td>OP0225 Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib + methotrexate: a randomised, placebo-controlled substudy of OPAL balance</td>
</tr>
<tr>
<td>Maladies auto-immunes</td>
<td>10h35-10h45</td>
<td>OP0249 Long-term extension results of RISE-SSc, a randomized trial of riociguat in patients with early diffuse cutaneous systemic sclerosis (dcSSc)</td>
</tr>
<tr>
<td>Polyarthrite rhumatoïde</td>
<td>10h45-10h50</td>
<td>OP0237 Thromboembolic safety profile of tofacitinib and baricitinib: an analysis of WHO VigiBase</td>
</tr>
<tr>
<td>Maladies auto-immunes</td>
<td>10h45-10h55</td>
<td>OP0250 Efficacy and safety of romilkimab in diffuse cutaneous systemic sclerosis (dcSSc): randomized, double-blind, placebo-controlled, 24-week, proof of concept study</td>
</tr>
<tr>
<td>Spondyloarthrite</td>
<td>10h55-11h05</td>
<td>OP0227 Secukinumab versus adalimumab head-to-head comparison in biologic-naive patients with active psoriatic arthritis through 52-weeks (EXCEED): a randomised, double-blind, phase-3b study</td>
</tr>
<tr>
<td>Polyarthrite rhumatoïde</td>
<td>11h05-11h15</td>
<td>OP0221 Have 5-year survival rate and mortality changed in patients with early rheumatoid arthritis in the past twenty years? Results from the IORRA cohort</td>
</tr>
<tr>
<td>Spondyloarthrite</td>
<td>11h05-11h15</td>
<td>OP0228 Efficacy and safety of ixekizumab versus adalimumab (SPIRIT-H2H) with and without concomitant conventional synthetic Disease-Modifying Antirheumatic Drugs (DMARD) in biologic DMARD-naïve patients with psoriatic arthritis: 52-week results</td>
</tr>
<tr>
<td>Polyarthrite rhumatoïde</td>
<td>11h15-11h25</td>
<td>OP0222 Is referring early arthritis patients within 6 weeks associated with better long-term outcomes than referring within 12 weeks after symptom onset? – Investigating the evidence for the first EULAR recommendation for early arthritis in two observational cohorts</td>
</tr>
<tr>
<td>Maladies auto-immunes</td>
<td>11h25-11h35</td>
<td>OP0277 AURORA phase 3 study demonstrates voclosporin statistical superiority over standard of care in lupus nephritis</td>
</tr>
<tr>
<td>Maladies auto-immunes</td>
<td>13h00-13h05</td>
<td>OP0302 lanalumab (VAY736), a dual mode of action biologic combining BAFF receptor inhibition with B cell depletion, reaches primary endpoint for treatment of primary Sjogren's syndrome</td>
</tr>
</tbody>
</table>
### SAMEDI 6 JUIN

<table>
<thead>
<tr>
<th>Thématique</th>
<th>Horaires</th>
<th>Abstracts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spondyloarthrite</td>
<td>10h30-12h00</td>
<td>SAT0398 Persistence of ustekinumab (UST) or TNF inhibitor (TNFI) treatment in psoriatic arthritis (PsA): insights from the large, prospective, multinational, real-world PsABio cohort</td>
</tr>
<tr>
<td>Polyarthrite rhumatoïde</td>
<td>10h30-12h10</td>
<td>SAT0066 Burden of malignancy, venous thromboembolism, anemia, and infections in patients with rheumatoid arthritis who switched from a first conventional synthetic disease-modifying antirheumatic drug to another disease-modifying antirheumatic drug regimen</td>
</tr>
<tr>
<td>Polyarthrite rhumatoïde</td>
<td>10h30-12h10</td>
<td>SAT0134 Comparative risk of cancer associated with first-line DMARDs use in rheumatoid arthritis: real world evidence from the OHDSI network</td>
</tr>
<tr>
<td>Polyarthrite rhumatoïde</td>
<td>10h30-12h10</td>
<td>SAT0130 Treat-to-target strategy of &gt;8,000 patients with early rheumatoid arthritis: Does smoking affect achievement of remission on methotrexate and time to start of first biologic? Results from the nationwide Danish DANBIO registry</td>
</tr>
<tr>
<td>Polyarthrite rhumatoïde</td>
<td>10h30-12h10</td>
<td>SAT0137 Methotrexate associated adverse events and their predictors in methotrexate-naive patients with rheumatoid arthritis: a systematic review</td>
</tr>
<tr>
<td>Polyarthrite rhumatoïde</td>
<td>10h30-12h10</td>
<td>SAT0071 Subclinical synovitis in arthralgia: how often does it result in clinical arthritis? A longitudinal study to reflect on starting points for DMARD treatment</td>
</tr>
<tr>
<td>Polyarthrite rhumatoïde</td>
<td>13h30-13h40</td>
<td>2019 Update of the EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease modifying antirheumatic drugs</td>
</tr>
<tr>
<td>Spondyloarthrite</td>
<td>13h40-13h50</td>
<td>2019 Update of the recommendations for the management of psoriatic arthritis with pharmacological therapies</td>
</tr>
</tbody>
</table>
Retrouvez en vidéo chaque thématique et sélection commentées par les experts

Et retrouvez l’intégralité de l’émission spéciale sur
→ www.edimark.fr/EULAR/2020/esp